AP2015008441A0 - Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors - Google Patents
Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressorsInfo
- Publication number
- AP2015008441A0 AP2015008441A0 AP2015008441A AP2015008441A AP2015008441A0 AP 2015008441 A0 AP2015008441 A0 AP 2015008441A0 AP 2015008441 A AP2015008441 A AP 2015008441A AP 2015008441 A AP2015008441 A AP 2015008441A AP 2015008441 A0 AP2015008441 A0 AP 2015008441A0
- Authority
- AP
- ARIPO
- Prior art keywords
- pyrimido
- diones
- quinoline
- nonsense mutation
- mutation suppressors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Inorganic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736748P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/060859 WO2014091446A1 (fr) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilisés en tant que suppresseurs de mutation non-sens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2015008441A0 true AP2015008441A0 (en) | 2015-05-31 |
Family
ID=50030361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008441A AP2015008441A0 (en) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9649314B2 (fr) |
| EP (1) | EP2931282B1 (fr) |
| JP (1) | JP6076498B2 (fr) |
| KR (1) | KR101760586B1 (fr) |
| CN (2) | CN104837490B (fr) |
| AP (1) | AP2015008441A0 (fr) |
| AU (1) | AU2013358591B2 (fr) |
| BR (1) | BR112015013535A2 (fr) |
| CA (1) | CA2890692A1 (fr) |
| CL (1) | CL2015001610A1 (fr) |
| CR (1) | CR20150314A (fr) |
| CU (1) | CU20150061A7 (fr) |
| EA (1) | EA028673B1 (fr) |
| ES (1) | ES2709034T3 (fr) |
| HK (1) | HK1209637A1 (fr) |
| IL (1) | IL239244A0 (fr) |
| IN (1) | IN2015DN03998A (fr) |
| MA (1) | MA38157A1 (fr) |
| MX (1) | MX363437B (fr) |
| PE (1) | PE20151062A1 (fr) |
| PH (1) | PH12015501216A1 (fr) |
| SG (1) | SG11201503684WA (fr) |
| TN (1) | TN2015000262A1 (fr) |
| WO (1) | WO2014091446A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013358591B2 (en) | 2012-12-13 | 2016-08-25 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors |
| WO2015186061A1 (fr) * | 2014-06-03 | 2015-12-10 | Novartis Ag | Dérivés de pyridopyrimidinedione |
| JP6560257B2 (ja) * | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体 |
| TN2016000490A1 (en) * | 2014-06-03 | 2018-04-04 | Novartis Ag | Naphthyridinedione derivatives. |
| CN109152747A (zh) * | 2016-04-15 | 2019-01-04 | Uab研究基金会 | 用于刺激提前终止密码子的通读的方法和化合物 |
| WO2019173437A1 (fr) * | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulateurs allostériques positifs du récepteur de la dopamine 1 et procédé d'utilisation associé |
| WO2019225625A1 (fr) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | Inducteur de translecture et utilisation pharmaceutique associée |
| EP4211171A2 (fr) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Fragment d'anticorps contre fap |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
| WO2023203135A1 (fr) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Anticorps radiomarqué amélioré |
| WO2023213801A1 (fr) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pré-ciblage |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| US5908930A (en) | 1995-03-15 | 1999-06-01 | Pfizer Inc. | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004078163A2 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
| WO2004006906A2 (fr) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methodes de traitement de neoplasmes |
| HUE031794T2 (en) | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
| ES2594343T3 (es) | 2006-04-03 | 2016-12-19 | Technion Research & Development Foundation Limited | Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos |
| AU2007288198A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| WO2009086303A2 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| EP2422817A1 (fr) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Conjugués flavine-ligand d'acide nucléique |
| EP2600865B1 (fr) | 2010-08-05 | 2018-11-14 | Université de Lille | Composé utile pour le traitement de maladies médiées par une mutation non-sens et composition pharmaceutique comprenant ledit composé |
| AU2013358591B2 (en) | 2012-12-13 | 2016-08-25 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors |
-
2013
- 2013-12-12 AU AU2013358591A patent/AU2013358591B2/en not_active Ceased
- 2013-12-12 AP AP2015008441A patent/AP2015008441A0/xx unknown
- 2013-12-12 JP JP2015547244A patent/JP6076498B2/ja not_active Expired - Fee Related
- 2013-12-12 SG SG11201503684WA patent/SG11201503684WA/en unknown
- 2013-12-12 KR KR1020157018231A patent/KR101760586B1/ko active IP Right Grant
- 2013-12-12 CA CA2890692A patent/CA2890692A1/fr not_active Abandoned
- 2013-12-12 EP EP13826612.7A patent/EP2931282B1/fr active Active
- 2013-12-12 MX MX2015007562A patent/MX363437B/es unknown
- 2013-12-12 US US14/652,102 patent/US9649314B2/en not_active Expired - Fee Related
- 2013-12-12 CN CN201380064035.5A patent/CN104837490B/zh not_active Expired - Fee Related
- 2013-12-12 WO PCT/IB2013/060859 patent/WO2014091446A1/fr active Application Filing
- 2013-12-12 PE PE2015000911A patent/PE20151062A1/es not_active Application Discontinuation
- 2013-12-12 CN CN201710826258.0A patent/CN107569487A/zh active Pending
- 2013-12-12 BR BR112015013535A patent/BR112015013535A2/pt not_active Application Discontinuation
- 2013-12-12 EA EA201591105A patent/EA028673B1/ru not_active IP Right Cessation
- 2013-12-12 IN IN3998DEN2015 patent/IN2015DN03998A/en unknown
- 2013-12-12 ES ES13826612T patent/ES2709034T3/es active Active
-
2015
- 2015-05-29 PH PH12015501216A patent/PH12015501216A1/en unknown
- 2015-06-04 IL IL239244A patent/IL239244A0/en unknown
- 2015-06-05 MA MA38157A patent/MA38157A1/fr unknown
- 2015-06-09 TN TNP2015000262A patent/TN2015000262A1/fr unknown
- 2015-06-10 CL CL2015001610A patent/CL2015001610A1/es unknown
- 2015-06-12 CU CUP2015000061A patent/CU20150061A7/es unknown
- 2015-06-12 CR CR20150314A patent/CR20150314A/es unknown
- 2015-10-23 HK HK15110447.1A patent/HK1209637A1/xx unknown
-
2017
- 2017-04-04 US US15/478,778 patent/US20170266189A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239244A0 (en) | Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations | |
| HRP20181349T1 (hr) | Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina | |
| HK1246792A1 (zh) | 6，7-二氫吡唑並[1，5-a]吡嗪-4(5h)-酮化合物 | |
| ZA201408843B (en) | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor | |
| HK1206014A1 (en) | Pyrazolo triazine derivatives as selective cyclin dependent kinase inhinitors | |
| HK1210167A1 (en) | Macrocycle picolinamides as fungicides -2- | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| IL243092A0 (en) | New triazolo[d–4,5]pyrimidine histories | |
| EP2968311A4 (fr) | Composés d'oxazolo[5,4-c]quinolin-2-one en tant qu'inhibiteurs de bromodomaines | |
| HK1199879A1 (en) | Pde9 inhibitors with imidazo triazinone backbone pde9 | |
| ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| PL3129374T3 (pl) | (5,6-Dihydro)pirymido[4,5-e]indolizyny | |
| HK1187614A1 (zh) | 咪唑並吡嗪 | |
| EP2925877A4 (fr) | Procédé de broyage | |
| EP2925876A4 (fr) | Procédé de broyage | |
| HK1206354A1 (en) | Pyrrolo[2,3-b]pyrazines as syk inhibitors syk [23-b] | |
| HK1220196A1 (zh) | 抗病毒吲哚並 喹喔啉 | |
| EP2925790A4 (fr) | Procédé de broyage | |
| HK1209419A1 (en) | Solid form of dihydro pyrido oxazine derivative | |
| GB2501283B (en) | Microbiological safety cabinets | |
| GB201211756D0 (en) | Novel isothiazolo [4,3-b]pyridines | |
| GB201219129D0 (en) | Triazolo(4,5-d)pyrmindine compounds | |
| AU344103S (en) | Modular outdoor seating |